Physician profile
Yuchi C Chang
NPI 1083804439
$6,636.97
in general payments reported to CMS, 2019-2025
29 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $279 · 2021: $796 · 2022: $881 · 2023: $1,375 · 2024: $1,338 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,785.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.72 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $899.01 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $783.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $779.92 | 2019-2025 | |
| Lilly USA, LLC | $521.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $515.20 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $500.49 | 2019-2025 | Tremfya |
| Ucb, INC. | $387.83 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $240.76 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $122.28 | 2019 | |
| Amgen INC. | $118.59 | 2020-2023 | Otezla |
| Incyte Corporation | $110.39 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.80 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Galderma Laboratories, L.P. | $77.17 | 2019-2022 | |
| Journey Medical Corporation | $72.75 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $67.06 | 2025 | Adbry, Anzupgo |
| Celgene Corporation | $66.53 | 2019 | |
| Epi Health, LLC | $66.10 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $47.71 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $35.34 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $33.11 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $27.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.69 | 2025 | Sotyktu |
| Allergan, INC. | $26.60 | 2019-2021 | |
| Almirall LLC | $23.04 | 2021 | |
| Organogenesis INC. | $22.76 | 2023 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.15 | 2023 | Spevigo |
| Biofrontera INC. | $17.61 | 2021 | |
| Botanix Sb INC | $17.12 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuchi Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.